High expression of neuropeptide Y1 receptors in ewing sarcoma tumors

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5043-5049

  Körner, Meike ^a   Waser, Beatrice ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; MESSENGER RNA; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y Y1 RECEPTOR; NEUROPEPTIDE Y-Y1 RECEPTOR; TUMOR MARKER;

ANGIOSARCOMA; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CHONDROSARCOMA; CONTROLLED STUDY; DESMOID TUMOR; EWING SARCOMA; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LEIOMYOSARCOMA; LIPOSARCOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SYNOVIAL SARCOMA; TUMOR CELL; ARTERY; BIOSYNTHESIS; BONE TUMOR; GENE EXPRESSION; METABOLISM; SARCOMA; SOFT TISSUE TUMOR; VASCULARIZATION;

ARTERIES; AUTORADIOGRAPHY; BONE NEOPLASMS; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; RECEPTORS, NEUROPEPTIDE Y; RNA, MESSENGER; SARCOMA; SARCOMA, EWING'S; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 52649149098     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4551     Document Type: Article

References (34)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
2. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996;125:26-34.
3. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-D0TA0Xyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62.
4. Reubi JC, Gugger M,Waser B, SchaerJC. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001;61:4636-41.
5. Körner M, Reubi JC. NPY receptors in human cancer:a review of current knowledge. Peptides 2007;28:419-25.
6. Michel MC, Beck-Sickinger A, Cox H, et al. XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol Rev 1998;50:143-50.
7. Körner M,Waser B, Reubi JC. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 2004;84:71 -80.
8. Körner M,Waser B, Reubi JC. High expression of NPY receptors in tumors of the human adrenal gland and extraadrenal paraganglia. Clin Cancer Res 2004;10:8426-33.
9. Körner M,Waser B, Reubi JC. Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. Int J Cancer 2005;115:734-41.
10. Balasubramaniam A. Clinical potentials of neuropeptide Y family of hormones. Am J Surg 2002;183:430-4.
11. Olasmaa M, Pahlman S,Terenius L.β-adrenoceptor,vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) receptors functionally coupled to adenylate cyclase in the human neuroblastoma SK-N-MC cell line. Neurosci Lett 1987;83:161 -6.
12. van Valen F, Winkelmann W, Jurgens H. Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines. J Cancer Res Clin Oncol 1992;118:529-36.
13. Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H, Wahlested C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem 1992;267:10935-8.
14. Bader JE, Deckert CM, Koglin N, et al. From transcription profile to expression: the signaling repertoire of the SK-N-MC neuroepithelioma cell-line. J Recept Signal Transduct Res 2004;24:257-82.
15. Bjurholm A, Kreicbergs A, Schultzberg M, Lerner UH. Parathyroid hormone and noradrenaline-induced enhancement of cyclic AMP in a cloned osteogenic sarcoma cell line (UMR106) is inhibited by neuropeptide Y. Acta Physiol Scand 1988;134:451 -2.
16. Togari A, Arai M, Mizutani S, Mizutani S, Koshihara Y, Nagatsu T. Expression of mRNAs for neuropeptide receptors and (1-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 1997;233:125-8.
17. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 2003;40:276-87.
18. Randall RL, Schabel KL, Hitchcock Y, Joyner DE, Albritton KH. Diagnosis and management of synovial sarcoma. CurrTreat Options Oncol 2005;6:449-59.
19. Reubi JC, Waser B, Laissue JA, Gebbers JO. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res 1996;56:1922-31.
20. Reubi JC, Waser B, Schaer JC, Laissue JA. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int J Cancer 1999;82:213-8.
21. Schaer JC, Reubi JC. High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents. J Clin Endocrinol Metab 1999;84:233-9.
22. Cabrele C, Wieland HA, Koglin N, Stidsen C, Beck-Sickinger AG. Ala31-32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry 2002;41:8043-9.
23. Dumont Y, Jacques D, Bouchard P, Quirion R. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J Comp Neurol 1998;402:372-84.
24. Reubi JC, Körner M.Waser B, Mazzucchelli L, Guillou L High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004;31:803-10.
25. Lobaugh LA, Blackshear PJ. Neuropeptide Y binding and inhibition of cAMP accumulation in human neuroepithelioma cells. Am J Physiol 1990;258: C913-22.
26. Bjurholm A, Kreicbergs A, Schultzberg M, Lerner UH. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/ 2.8, MC3T3-1, and Saos-2) and primary bone cells. J Bone Miner Res 1992;7:1011 -9.
27. Kitlinska J, Abe K, Kuo L, et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 2005;65:1719-28.
28. Pernow J, Ohlén A, HökfeltT, Nilsson 0, Lundberg JM. Neuropeptide Y: presence in perivascular noradrenergic neurons and vasoconstrictor effects on skeletal muscle blood vessels in experimental animals and man. Regul Pept 1987;19:313-24.
29. Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H, Beck-Sickinger AG. Novel peptide conjugates for tumor-specific chemotherapy. J Med Chem 2001;44:1341 -8.
30. Langer M, La Bella R, Garcia-Garayoa E, Beck-Sickinger AG. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Biocon-jug Chem 2001;12:1028-34.
31. Teunissen JJ, Kwekkeboom DJ, deJong M, Esser JP, Valkema R, Krenning EP. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005;19:595-616.
32. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006;103:16436-41.
33. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohisto-chemical study. Am J Surg Pathol 2002;26:486-92.
34. Thomas DG, GiordanoTJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005;103:830-8.